CA2829606C - Methods and reagents for creating monoclonal antibodies - Google Patents
Methods and reagents for creating monoclonal antibodies Download PDFInfo
- Publication number
- CA2829606C CA2829606C CA2829606A CA2829606A CA2829606C CA 2829606 C CA2829606 C CA 2829606C CA 2829606 A CA2829606 A CA 2829606A CA 2829606 A CA2829606 A CA 2829606A CA 2829606 C CA2829606 C CA 2829606C
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- immunoglobulin
- nucleic acid
- acid sequences
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 220
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 46
- 239000000427 antigen Substances 0.000 claims abstract description 358
- 108091007433 antigens Proteins 0.000 claims abstract description 358
- 102000036639 antigens Human genes 0.000 claims abstract description 358
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 270
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 270
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 239
- 241001465754 Metazoa Species 0.000 claims abstract description 181
- 238000001819 mass spectrum Methods 0.000 claims abstract description 121
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 95
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 95
- 229940072221 immunoglobulins Drugs 0.000 claims abstract description 84
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 70
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 61
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims abstract description 45
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims abstract description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 213
- 108090000623 proteins and genes Proteins 0.000 claims description 162
- 102000004169 proteins and genes Human genes 0.000 claims description 125
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 106
- 230000027455 binding Effects 0.000 claims description 67
- 241000282414 Homo sapiens Species 0.000 claims description 65
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 64
- 108020004414 DNA Proteins 0.000 claims description 62
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 55
- 238000001228 spectrum Methods 0.000 claims description 50
- 239000004365 Protease Substances 0.000 claims description 44
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 42
- 238000000746 purification Methods 0.000 claims description 42
- 102000035195 Peptidases Human genes 0.000 claims description 41
- 108091005804 Peptidases Proteins 0.000 claims description 41
- 230000003321 amplification Effects 0.000 claims description 38
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 38
- 238000002965 ELISA Methods 0.000 claims description 37
- 238000001262 western blot Methods 0.000 claims description 33
- 238000003556 assay Methods 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 26
- 230000007026 protein scission Effects 0.000 claims description 19
- 241000894007 species Species 0.000 claims description 15
- 101710120037 Toxin CcdB Proteins 0.000 claims description 13
- 238000000684 flow cytometry Methods 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 238000003018 immunoassay Methods 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 11
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000010166 immunofluorescence Methods 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 238000003364 immunohistochemistry Methods 0.000 claims description 8
- 238000001823 molecular biology technique Methods 0.000 claims description 8
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 7
- 238000001261 affinity purification Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 238000006386 neutralization reaction Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 238000001114 immunoprecipitation Methods 0.000 claims description 4
- 238000000159 protein binding assay Methods 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000003567 ascitic fluid Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
- 238000000730 protein immunoprecipitation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 124
- 210000003719 b-lymphocyte Anatomy 0.000 description 113
- 238000003752 polymerase chain reaction Methods 0.000 description 85
- 150000001413 amino acids Chemical group 0.000 description 83
- 239000011324 bead Substances 0.000 description 82
- 239000000203 mixture Substances 0.000 description 81
- 238000012163 sequencing technique Methods 0.000 description 72
- 235000018102 proteins Nutrition 0.000 description 66
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 65
- 239000012634 fragment Substances 0.000 description 62
- 238000004949 mass spectrometry Methods 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 50
- 239000002299 complementary DNA Substances 0.000 description 43
- 108091093088 Amplicon Proteins 0.000 description 42
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 42
- 239000002953 phosphate buffered saline Substances 0.000 description 42
- 201000010099 disease Diseases 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 238000007481 next generation sequencing Methods 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 36
- 210000002381 plasma Anatomy 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 239000000872 buffer Substances 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 32
- 230000002441 reversible effect Effects 0.000 description 32
- 238000004885 tandem mass spectrometry Methods 0.000 description 32
- 239000000523 sample Substances 0.000 description 31
- 229920001184 polypeptide Polymers 0.000 description 30
- 238000005516 engineering process Methods 0.000 description 29
- 230000000670 limiting effect Effects 0.000 description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 27
- 150000002500 ions Chemical class 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 235000019419 proteases Nutrition 0.000 description 20
- 238000002955 isolation Methods 0.000 description 19
- 238000003757 reverse transcription PCR Methods 0.000 description 19
- 108090000631 Trypsin Proteins 0.000 description 18
- 102000004142 Trypsin Human genes 0.000 description 18
- 238000013459 approach Methods 0.000 description 18
- 239000012588 trypsin Substances 0.000 description 18
- 229960001322 trypsin Drugs 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 230000029087 digestion Effects 0.000 description 16
- 239000000839 emulsion Substances 0.000 description 16
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000004927 fusion Effects 0.000 description 15
- 238000012408 PCR amplification Methods 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 210000004988 splenocyte Anatomy 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 230000002596 correlated effect Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108090000284 Pepsin A Proteins 0.000 description 12
- 102000057297 Pepsin A Human genes 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 229940111202 pepsin Drugs 0.000 description 12
- 229920000136 polysorbate Polymers 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000010561 standard procedure Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 108090000317 Chymotrypsin Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229960002376 chymotrypsin Drugs 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000002502 liposome Substances 0.000 description 11
- 230000009257 reactivity Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 9
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 238000000126 in silico method Methods 0.000 description 8
- 210000001806 memory b lymphocyte Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000010847 SEQUEST Methods 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004811 liquid chromatography Methods 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 102100027207 CD27 antigen Human genes 0.000 description 6
- -1 CD78 Proteins 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 238000002123 RNA extraction Methods 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 108010090371 progesterone receptor B Proteins 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229940043517 specific immunoglobulins Drugs 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 108090000526 Papain Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000012350 deep sequencing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 108010090388 progesterone receptor A Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 229910052719 titanium Inorganic materials 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001077 electron transfer detection Methods 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012175 pyrosequencing Methods 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 235000002198 Annona diversifolia Nutrition 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000005210 lymphoid organ Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000000955 peptide mass fingerprinting Methods 0.000 description 3
- 238000013081 phylogenetic analysis Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003608 titanium Chemical class 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150086096 Eif2ak3 gene Proteins 0.000 description 2
- 241000289669 Erinaceus europaeus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000012176 true single molecule sequencing Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010082845 Bacteriorhodopsins Proteins 0.000 description 1
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 102100032145 Carbohydrate sulfotransferase 10 Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102100029172 Choline-phosphate cytidylyltransferase A Human genes 0.000 description 1
- 101710100763 Choline-phosphate cytidylyltransferase A Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 241000611421 Elia Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101100275686 Homo sapiens CR2 gene Proteins 0.000 description 1
- 101000775595 Homo sapiens Carbohydrate sulfotransferase 10 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000738977 Homo sapiens Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229940125895 MET kinase inhibitor Drugs 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 101100275687 Mus musculus Cr2 gene Proteins 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101800003414 Pro-elastase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100036014 T-cell surface glycoprotein CD1c Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 241001648840 Thosea asigna virus Species 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940043292 chymotrypsin / trypsin Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000004667 early pro-b cell Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000007625 higher-energy collisional dissociation Methods 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000014 large pre-b cell Anatomy 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000012132 radioimmunoprecipitation assay buffer Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 210000000345 small pre-b cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161450922P | 2011-03-09 | 2011-03-09 | |
| US61/450,922 | 2011-03-09 | ||
| US201161560006P | 2011-11-15 | 2011-11-15 | |
| US61/560,006 | 2011-11-15 | ||
| US201161566876P | 2011-12-05 | 2011-12-05 | |
| US61/566,876 | 2011-12-05 | ||
| US201261594729P | 2012-02-03 | 2012-02-03 | |
| US61/594,729 | 2012-02-03 | ||
| PCT/US2012/028501 WO2012122484A1 (en) | 2011-03-09 | 2012-03-09 | Methods and reagents for creating monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2829606A1 CA2829606A1 (en) | 2012-09-13 |
| CA2829606C true CA2829606C (en) | 2020-06-02 |
Family
ID=45922811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2829606A Active CA2829606C (en) | 2011-03-09 | 2012-03-09 | Methods and reagents for creating monoclonal antibodies |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9920110B2 (enExample) |
| EP (2) | EP3345922A1 (enExample) |
| JP (3) | JP6211931B2 (enExample) |
| KR (3) | KR20190006083A (enExample) |
| CN (2) | CN103842379A (enExample) |
| AU (3) | AU2012225310B2 (enExample) |
| CA (1) | CA2829606C (enExample) |
| DK (1) | DK2683736T3 (enExample) |
| ES (1) | ES2666301T3 (enExample) |
| HK (1) | HK1256304A1 (enExample) |
| HU (1) | HUE037095T2 (enExample) |
| WO (1) | WO2012122484A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8685898B2 (en) | 2009-01-15 | 2014-04-01 | Imdaptive, Inc. | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
| EP2783214A2 (en) | 2011-11-23 | 2014-10-01 | The Board of Regents of The University of Texas System | Proteomic identification of antibodies |
| US10077478B2 (en) | 2012-03-05 | 2018-09-18 | Adaptive Biotechnologies Corp. | Determining paired immune receptor chains from frequency matched subunits |
| MX354329B (es) | 2012-05-08 | 2018-02-27 | Adaptive Biotechnologies Corp | Composiciones y metodos para medir y calibrar el error de amplificacion en reacciones de pcr multiple. |
| CN104619862B (zh) | 2012-06-15 | 2017-10-31 | 得克萨斯系统大学董事会 | 单细胞的多转录物的高通量测序 |
| WO2015160439A2 (en) | 2014-04-17 | 2015-10-22 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| SG10201707394PA (en) * | 2013-03-15 | 2017-10-30 | Adaptive Biotechnologies Corp | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| JP5924455B2 (ja) * | 2013-09-09 | 2016-05-25 | 株式会社島津製作所 | ペプチド断片の調製方法およびそれに用いられるペプチド断片調製用キット、ならびに分析方法 |
| GB201316644D0 (en) * | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| WO2015200626A1 (en) * | 2014-06-25 | 2015-12-30 | The Rockefeller University | Compositions and methods for rapid production of versatile nanobody repertoires |
| CN105277638A (zh) * | 2014-07-22 | 2016-01-27 | 沈鹤霄 | 一种单克隆抗体IgG质谱测序方法 |
| ES2784343T3 (es) | 2014-10-29 | 2020-09-24 | Adaptive Biotechnologies Corp | Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras |
| US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
| CN104560980B (zh) * | 2015-01-20 | 2017-04-05 | 中国人民解放军第三军医大学 | 基于高通量测序构建鼠BCR轻链Lamda文库的多重PCR引物和方法 |
| CN104560979B (zh) * | 2015-01-20 | 2017-04-05 | 中国人民解放军第三军医大学 | 基于高通量测序构建鼠bcr重链文库的多重pcr引物和方法 |
| US11047008B2 (en) | 2015-02-24 | 2021-06-29 | Adaptive Biotechnologies Corporation | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
| GB2555921B (en) | 2015-03-06 | 2021-09-15 | Micromass Ltd | Endoscopic tissue identification tool |
| GB2553918B (en) | 2015-03-06 | 2022-10-12 | Micromass Ltd | Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue |
| CA2981085A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Spectrometric analysis |
| CN110057901B (zh) * | 2015-03-06 | 2022-07-01 | 英国质谱公司 | 拭子和活检样品的快速蒸发电离质谱和解吸电喷雾电离质谱分析 |
| CN108700590B (zh) | 2015-03-06 | 2021-03-02 | 英国质谱公司 | 细胞群体分析 |
| US11282688B2 (en) | 2015-03-06 | 2022-03-22 | Micromass Uk Limited | Spectrometric analysis of microbes |
| CA2978042A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Tissue analysis by mass spectrometry or ion mobility spectrometry |
| US10513733B2 (en) | 2015-03-23 | 2019-12-24 | Board Of Regents, The University Of Texas System | High throughout sequencing of paired VH and VL transcripts from B cells secreting antigen-specific antibodies |
| EP3277294B1 (en) | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| WO2017044885A1 (en) * | 2015-09-09 | 2017-03-16 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health |
| US11454611B2 (en) | 2016-04-14 | 2022-09-27 | Micromass Uk Limited | Spectrometric analysis of plants |
| CN106047857B (zh) * | 2016-06-01 | 2020-04-03 | 苏州金唯智生物科技有限公司 | 一种发掘特异性功能抗体的方法 |
| CN107525934A (zh) * | 2016-06-21 | 2017-12-29 | 张效龙 | 一种测定血液中抗体氨基酸序列的方法 |
| US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
| CN110382696B (zh) * | 2017-03-07 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 发现替代性抗原特异性抗体变体的方法 |
| AU2018303254B2 (en) * | 2017-07-21 | 2025-05-29 | Novimmune Sa | Generating multispecific antibody mixtures and methods of uses thereof |
| CN109425662A (zh) * | 2017-08-23 | 2019-03-05 | 深圳华大基因研究院 | 一种鉴定蛋白的方法及系统 |
| WO2019084538A1 (en) | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF |
| US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| JP2020514681A (ja) * | 2018-03-29 | 2020-05-21 | 深▲セン▼▲達▼▲闥▼科技控股有限公司Ｃｌｏｕｄｍｉｎｄｓ （Ｓｈｅｎｚｈｅｎ） Ｈｏｌｄｉｎｇｓ Ｃｏ．， Ｌｔｄ． | 物質検出方法、装置、電子機器、およびコンピュータ可読記憶媒体 |
| CN108530533B (zh) * | 2018-04-13 | 2020-09-04 | 吉林大学 | 猪瘟病毒单克隆抗体hk24及医用用途 |
| EP3894867A4 (en) * | 2018-12-11 | 2022-09-28 | Merck Sharp & Dohme Corp. | PROCEDURE FOR IDENTIFICATION OF HIGH-AFFINITY MONOCLONAL ANTIBODIES OF HEAVY AND LIGHT CHAIN FROM HIGH-THROUGHPUT SCREENS OF B-CELL AND HYBRIDOME LIBRARIES |
| JP7516368B2 (ja) * | 2019-06-07 | 2024-07-16 | 中外製薬株式会社 | 情報処理システム、情報処理方法、プログラム、及び、抗原結合分子或いはタンパク質を製造する方法 |
| CN110452296A (zh) * | 2019-07-16 | 2019-11-15 | 福州精锐生物技术有限公司 | 一种兔单克隆抗体制备方法 |
| MX2022003244A (es) * | 2019-09-16 | 2022-04-26 | Regeneron Pharma | Metodos de lc-ms para la isotipificacion y cuantificacion de anticuerpos. |
| CN115175919A (zh) * | 2019-12-09 | 2022-10-11 | 光行科技株式会社 | 转换结合剂、其制备方法、和各自使用该转换结合剂的药物组合物、测定试剂盒、以及抗原和抗体测定方法 |
| JP7765090B2 (ja) * | 2020-05-01 | 2025-11-06 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ナノボディ及びナノボディ親和性を同定するための組成物及び方法 |
| EP4320148A4 (en) * | 2021-04-09 | 2025-05-14 | Abterra Biosciences, Inc. | METHOD FOR IDENTIFYING ANTIBODIES FROM PROTEIN MIXTURES |
| IT202100019334A1 (it) * | 2021-07-21 | 2023-01-21 | Univ Degli Studi Di Pavia | Metodo per l’identificazione dell’intera sequenza della regione variabile delle catene pesanti e leggere di immunoglobuline |
| CN115894687B (zh) * | 2022-03-31 | 2024-06-07 | 台州恩泽医疗中心(集团) | 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途 |
| CN116779037B (zh) * | 2022-07-27 | 2025-08-05 | 北京理工大学 | 一种基于从头测序和同源标签图论的抗体序列鉴定方法 |
| CN117849159B (zh) * | 2024-01-09 | 2025-01-07 | 融智生物科技（青岛）有限公司 | M蛋白的检测方法、电子设备及存储介质 |
| CN120214310B (zh) * | 2025-05-20 | 2025-08-19 | 中国农业大学 | 一种禽白血病抗原检测试剂盒及其制备方法 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| AU688751B2 (en) | 1993-01-12 | 1998-03-19 | Biogen Idec Ma Inc. | Recombinant anti-VLA4 antibody molecules |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5750341A (en) | 1995-04-17 | 1998-05-12 | Lynx Therapeutics, Inc. | DNA sequencing by parallel oligonucleotide extensions |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| EP1082458A1 (en) | 1998-05-01 | 2001-03-14 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and dna molecules |
| US6780591B2 (en) | 1998-05-01 | 2004-08-24 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
| US7300753B2 (en) | 1998-09-04 | 2007-11-27 | John Rush | Immunoaffinity isolation of modified peptides from complex mixtures |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| US7244559B2 (en) | 1999-09-16 | 2007-07-17 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
| US7211390B2 (en) | 1999-09-16 | 2007-05-01 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
| DE60239962D1 (de) | 2001-08-14 | 2011-06-16 | Harvard College | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie |
| EP1458736A4 (en) * | 2001-12-14 | 2005-09-14 | Lilly Co Eli | RECOMBINANT RINDER THROMBIN |
| GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| CA2526120A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
| WO2005077106A2 (en) | 2004-02-09 | 2005-08-25 | Northeastern University | Monoclonal antibody based biomarker discovery and development platform |
| CA2557841A1 (en) | 2004-02-27 | 2005-09-09 | President And Fellows Of Harvard College | Polony fluorescent in situ sequencing beads |
| US20070161001A1 (en) | 2004-03-04 | 2007-07-12 | Dena Leshkowitz | Quantifying and profiling antibody and t cell receptor gene expression |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| SI1891088T1 (sl) * | 2005-06-10 | 2012-02-29 | Ares Trading Sa | Postopek za äśiĺ äśenje il-18 vezavnega proteina |
| AR059432A1 (es) | 2006-02-10 | 2008-04-09 | Genentech Inc | Anticuerpos anti-fgf19 y metodos que usan estos |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| CA2657223A1 (en) * | 2006-07-07 | 2008-01-10 | Pall Corporation | Use of denaturing agents during affinity capture |
| JP2010515020A (ja) | 2006-12-21 | 2010-05-06 | ノバルティス アーゲー | 抗体定量法 |
| EP2132229B1 (en) | 2007-03-01 | 2016-05-11 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| KR20090127341A (ko) | 2007-03-06 | 2009-12-10 | 심포젠 에이/에스 | 호흡기세포 융합 바이러스 감염 치료용 재조합 항체 |
| PL2125894T3 (pl) | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| EP2336329B8 (en) | 2007-06-01 | 2012-11-21 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies |
| US7887801B2 (en) | 2007-07-13 | 2011-02-15 | Topotarget Germany Ag | Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| JP4932940B2 (ja) * | 2007-11-12 | 2012-05-16 | セラクローン サイエンシーズ， インコーポレイテッド | インフルエンザの治療および診断のための組成物および方法 |
| CA2702322A1 (en) | 2007-11-22 | 2009-05-28 | Symphogen A/S | A method for characterization of a recombinant polyclonal protein |
| EP2088432A1 (en) | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
| WO2010002911A2 (en) | 2008-06-30 | 2010-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods and materials for monitoring myeloma using quantitative mass spetrometry |
| LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
| MX2011007660A (es) | 2008-12-18 | 2011-08-17 | Kingdon Craig R | Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos. |
| US8685898B2 (en) | 2009-01-15 | 2014-04-01 | Imdaptive, Inc. | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
| TR201818431T4 (tr) | 2009-02-25 | 2019-01-21 | Ucb Biopharma Sprl | Antikorlar Üretmek İçin Usul |
| PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
| US8293483B2 (en) | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
| ES2984483T3 (es) | 2010-03-31 | 2024-10-29 | Ablexis Llc | Ingeniería genética de ratones para la producción de anticuerpos quiméricos |
| US9234240B2 (en) | 2010-05-07 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| CA2799746C (en) | 2010-05-17 | 2020-11-24 | Sai Reddy | Rapid isolation of monoclonal antibodies from animals |
| CN103228130B (zh) | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
-
2012
- 2012-03-09 EP EP17196465.3A patent/EP3345922A1/en not_active Withdrawn
- 2012-03-09 CN CN201280021326.1A patent/CN103842379A/zh active Pending
- 2012-03-09 JP JP2013557906A patent/JP6211931B2/ja active Active
- 2012-03-09 CA CA2829606A patent/CA2829606C/en active Active
- 2012-03-09 WO PCT/US2012/028501 patent/WO2012122484A1/en not_active Ceased
- 2012-03-09 DK DK12711501.2T patent/DK2683736T3/en active
- 2012-03-09 US US13/416,582 patent/US9920110B2/en active Active
- 2012-03-09 AU AU2012225310A patent/AU2012225310B2/en active Active
- 2012-03-09 EP EP12711501.2A patent/EP2683736B1/en active Active
- 2012-03-09 ES ES12711501.2T patent/ES2666301T3/es active Active
- 2012-03-09 CN CN201810154961.6A patent/CN108220297A/zh active Pending
- 2012-03-09 KR KR1020197000660A patent/KR20190006083A/ko not_active Ceased
- 2012-03-09 KR KR1020137026647A patent/KR101938343B1/ko active Active
- 2012-03-09 HU HUE12711501A patent/HUE037095T2/hu unknown
- 2012-03-09 KR KR1020197026655A patent/KR20190107761A/ko not_active Ceased
-
2017
- 2017-09-13 JP JP2017175320A patent/JP6557709B2/ja not_active Expired - Fee Related
- 2017-10-12 AU AU2017245395A patent/AU2017245395B2/en active Active
-
2018
- 2018-01-19 US US15/875,615 patent/US20190002532A1/en not_active Abandoned
- 2018-11-30 HK HK18115369.1A patent/HK1256304A1/en unknown
-
2019
- 2019-07-11 JP JP2019128863A patent/JP2019195335A/ja active Pending
- 2019-08-14 AU AU2019216660A patent/AU2019216660A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140010436A (ko) | 2014-01-24 |
| EP3345922A1 (en) | 2018-07-11 |
| EP2683736B1 (en) | 2018-01-17 |
| AU2012225310B2 (en) | 2017-08-03 |
| DK2683736T3 (en) | 2018-04-23 |
| AU2019216660A1 (en) | 2019-09-05 |
| AU2012225310A1 (en) | 2013-09-26 |
| EP2683736A1 (en) | 2014-01-15 |
| JP2014509853A (ja) | 2014-04-24 |
| CN103842379A (zh) | 2014-06-04 |
| AU2017245395B2 (en) | 2019-05-16 |
| AU2017245395A1 (en) | 2017-11-02 |
| KR20190006083A (ko) | 2019-01-16 |
| AU2017245395A2 (en) | 2017-11-23 |
| US20120308555A1 (en) | 2012-12-06 |
| JP6557709B2 (ja) | 2019-08-07 |
| HUE037095T2 (hu) | 2018-08-28 |
| WO2012122484A1 (en) | 2012-09-13 |
| KR101938343B1 (ko) | 2019-01-14 |
| CN108220297A (zh) | 2018-06-29 |
| ES2666301T3 (es) | 2018-05-03 |
| KR20190107761A (ko) | 2019-09-20 |
| JP6211931B2 (ja) | 2017-10-11 |
| JP2019195335A (ja) | 2019-11-14 |
| CA2829606A1 (en) | 2012-09-13 |
| US20190002532A1 (en) | 2019-01-03 |
| JP2018027090A (ja) | 2018-02-22 |
| HK1256304A1 (en) | 2019-09-20 |
| US9920110B2 (en) | 2018-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2829606C (en) | Methods and reagents for creating monoclonal antibodies | |
| Nguyen et al. | Functional heavy-chain antibodies in Camelidae | |
| EP2310413B1 (en) | Camelid derived antigen binding polypeptides | |
| CN114126646B (zh) | 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位 | |
| EP3421592A1 (en) | Identification of polynucleotides associated with a sample | |
| JP2018148915A (ja) | 抗ｖａｓａ抗体、ならびにその産生法および使用法 | |
| Chassagne et al. | A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library | |
| HK1193825A (en) | Methods and reagents for creating monoclonal antibodies | |
| HK1193825B (en) | Methods and reagents for creating monoclonal antibodies | |
| TW202229328A (zh) | 抗原特異性抗體之鑑定及產生 | |
| US20130109586A1 (en) | Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid | |
| WO2021258114A1 (en) | Process for direct readout of immunoglobulins | |
| US12331133B2 (en) | Therapeutic antibodies for treating lung cancer | |
| CN111201239A (zh) | 用于开发特异于表位翻译后修饰状态的抗体的方法和组合物 | |
| CN117015302A (zh) | 抗原特异性抗体的鉴定和产生 | |
| WO2025238133A1 (en) | Multispecific antibody with binding specificity for il-11 and il-17 | |
| Almagro et al. | Novel approaches in discovery and design of antibody-based therapeutics | |
| IL210002A (en) | Polypeptides that bind to antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161212 |